functional-assessment-kinesin-7-cenp-e-spermatocytes-using-vivo

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using <em>In Vivo</em> Inhibition, Immunofluorescence and Flow Cytometry

In eukaryotes, meiosis is essential for genome stability and genetic diversity in sexual reproduction. Experimental analyses of spermatocytes in testes ...

Fujian Medical University

Fujian Province University

To investigate the inhibitory effect of photodynamic therapy (PDT) in combination with paclitaxel (PCT) on proliferation in esophageal carcinoma Eca-109 cells line.

[Inhibitory effect of photodynamic therapy combined with paclitaxel on the proliferation of esophageal carcinoma Eca-109 cells].

To study the chemical constituents of Vitex trifolia.

[Studies on the triterpenoids of Vitex trifolia].

To study the chemical constituents of Wedelia prostrata.

[Studies on the diterpenoids of Wedelia prostrata].

A new chiro-inositol ester, 4-hydroxyphenylacetyl-3-d-chiro-inositol ester (1), was isolated from the whole plants of Prenanthes macrophylla Franch., along with 10 known compounds, 4-hydroxyphenylacetic acid (2), trans-ethyl caffeate (3), cis-ethyl caffeate (4), protocatechualdehyde (5), luteolin (6), luteolin-7-O-β-d-glucoside (7), 15-hydroxy-2-oxo-guai-3-en-1α,5α,6β,7α,10α,11βH-12,6-olide (8), 15-glucopyranosyloxy-2-oxo-guaia-3,11(13)-dien-1α,5α,6β,7α,10αH-12,6-olide (9), ursolic acid (10), and oleanolic acid (11). Their structures were elucidated on the basis of spectroscopic analyses including HR-ESI-MS, ESI-MS, (1)H and (13)C NMR, HSQC, HMBC, and ROESY, and chemical evidences.

A new inositol derivative from Prenanthes macrophylla.

The effectiveness and influence of surgery followed by adjuvant chemoradiotherapy (CRT) on the survival of patients with resectable esophageal carcinoma are still under debate. The outcomes of clinical trials have not been consistent. This study aimed to perform a meta-analysis of eligible published clinical trials to compare CRT with surgery without adjuvant chemoradiotherapy (non-CRT) for resectable esophageal carcinoma.

Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis.

Retinoid X receptor (RXR) has been demonstrated to play an important role in cardiac development and has been implicated in cardiovascular diseases. This study aimed to examine the effects of RXRα agonist bexarotene on pathological left ventricular hypertrophy (LVH) in a spontaneously hypertensive rat (SHR) model and the underlying mechanism.

Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.

This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with Paclitaxel (PTX) and Oxaliplatin (OXA) as first-line treatment for patients with advanced gastric cancer (AGC).

Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer.

One new indole-type alkaloid, -L-rhamnopyranosyl-(1→6)--D- glucopyranosyl 6-methoxy-3-indolecarbonate (), together with three known alkaloids (-), one aromatic acid () and five known saponins (-), was isolated from the roots of . Their structures were established by NMR spectroscopic analysis and acid hydrolysis. In  anti-inflammatory activity, -butanol extract was found to be potent against ear edema in mice, with inhibition rate of 48.7% at a dose of 800 mg/kg. Furthermore, compounds  and  obtained from the -butanol extract exhibited significant anti-inflammatory activities with inhibition rates of 50.9% and 54.7% at a dose of 200 mg/kg.

A new indole-type alkaloid from the roots of .

The aim of this retrospective analysis was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, 5-fluorouracil, and leucovorin (TFL) as first-line treatment in patients with advanced gastric cancer (AGC). One hundred and thirteen patients were enrolled in the study who were confirmed to have AGC by histopathology. These patients were treated with TFL: paclitaxel at a dose of 135 mg/m as a 3-h intravenous infusion on day 1, LV 400 mg/m as an intravenous infusion over 2 h on day 1, followed by 5-fluorouracil 2400 mg/m as an infusion over a 46-h period on 3 consecutive days. Cycles were repeated every 2 weeks. A total of 113 patients were assessed for their response to therapy. A total of three patients achieved complete responses and 46 patients achieved partial responses, yielding an overall objective response rate of 43.4% [95% confidence interval (CI): 34.3-52.5%]. Fifty-four cases of stable disease and 10 cases of progressive disease were observed in the remaining patients. The median time to progression and overall survival were 5.2 months (95% CI: 4.7-5.8 months) and 14.1 months (95% CI: 12.5-15.8 months), respectively. Toxicities were tolerable and moderate. The most common grade 3-4 toxicities included leukopenia (16.8%), neutropenia (17.7%), anemia (8.0%), thrombocytopenia (5.3%), and fatigue (6.2%). Combination chemotherapy with TFL offers an active and safe therapeutic approach for patients with AGC.

Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.

Preoperative radiotherapy followed by total mesorectal excision with adjuvant chemotherapy has been recommended as the preferred treatment method for locally advanced rectal cancer (LARC). Similar rates of local control, survival and toxicity were observed in preoperative long-course chemoradiotherapy (LCRT) (45-50.4 Gy in 25-28 fractions) and in short-course radiotherapy (SCRT) with 25 Gy over five fractions. Both regimens lower the local recurrence rates compared with that of surgery followed by postoperative radiotherapy. With the simplicity and lower cost of SCRT, a growing number of patients have been receiving SCRT as preoperative radiotherapy. However, the currently established SCRT (25 Gy over five fractions) followed immediately by surgery resulted in poor downstaging and sphincter preservation rate. The pathological complete response (pCR) rate is also markedly lower with SCRT than with LCRT (0.7%vs16%). Several studies recommended SCRT with delayed surgery for more than 4 weeks with expectation of improved pathological outcomes and fewer postoperative complications. While a number of clinical trials demonstrated a persistently better overall local control with SCRT than with LCRT, overall survival advantage has not been observed. Since survival is mainly depended on distant metastases, efforts should be made towards more effective pathological response and systemic treatment. Given the apparent advantages of SCRT, we aimed to establish a dose escalation of SCRT and sequential modified FOLFOX6 (mFOLFOX6) as preoperative therapy for LARC with objectives of achieving an optimal balance of safety, cost effectiveness and clinical outcome, and to support further investigation of this regimen in a phase II/III setting.

Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.

The value of platinum-based adjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) remains controversial, as does whether BRCA1 and BRCA2 (BRCA1/2) germline variants are associated with platinum treatment sensitivity.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy.

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).

To establish RP2D in Phase 1 and evaluate safety and efficacy of abivertinib in EGFR T790M+ NSCLC patients with disease progression from prior EGFR inhibitors in Phase 2.

Article	Year
[Inhibitory effect of photodynamic therapy combined with paclitaxel on the proliferation of esophageal carcinoma Eca-109 cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University\| PubMed ID: 20584640	2010
[Studies on the triterpenoids of Vitex trifolia]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials\| PubMed ID: 21049612	2010
[Studies on the diterpenoids of Wedelia prostrata]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials\| PubMed ID: 21823454	2011
A new inositol derivative from Prenanthes macrophylla. Journal of Asian natural products research\| PubMed ID: 22296160	2012
Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis. Chinese medical journal\| PubMed ID: 23506601	2013
Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway. American journal of hypertension\| PubMed ID: 24603314	2014
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Cancer chemotherapy and pharmacology\| PubMed ID: 29619507	2018
A new indole-type alkaloid from the roots of . Natural product research\| PubMed ID: 30518257	2019
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer. Anti-cancer drugs\| PubMed ID: 30520775	2019
Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical ... BMJ open\| PubMed ID: 30904869	2019
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology\| PubMed ID: 32789480	2020
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 33492986	2021
A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 34740925	2021

Xiao-Yan Lin

Biography

JoVE Journal Publications

Other Publications